STT06 / STCube Pharma - LARVOL DELTA

Discovery of ASTT-06, a potent type 1 allosteric trapper of Poly (ADP-ribose) polymerase 1 (PARP1) for improved cancer treatment | Poster Board #1608 (ACS-Sp 2024) - "These findings not only underscore the potential of ASTT-06 as a novel therapeutic agent for cancer treatment but also elucidate the significance of type 1 allosteric trapping in PARP1 inhibition. The development of ASTT-06 marks a significant advancement in our ongoing efforts to harness the therapeutic potential of PARP1 inhibition, with implications for the design of more effective cancer treatments."

Oncology • PARP1